

COMBINATION OF PREVEXXION[®] RN WITH VAXXITEK[®] HVT+IBD

When building a vaccination program for your flock including broilers, breeders, and other long-lived birds, achieving the right combination of vaccines is critical to your investment and remains the major challenge for sustainable control of this disease worldwide.

These two vaccines in one injection provide added protection for improved Marek’s disease virus (MD) and infectious bursal disease (IBD) coverage. Our vaccination solution provides protection against virulent and very virulent strains of MD plus variant and classic strains of IBD.

Vaccine contents:

PREVEXXION[®] RN: Marek’s Disease Vaccine Serotype 1, Live Herpesvirus Chimera

VAXXITEK[®] HVT+IBD: Bursal Disease – Marek’s Disease Vaccine, Serotype 3, Live Marek’s Disease Vector

PREVEXXION RN was efficacious when used in combination with a vectored vaccines such as VAXXITEK HVT+IBD^{1,2}. The protection is high against Marek’s disease RB1B challenge at four days of age^{1,2}.


Clinical protection provided by PREVEXXION RN & VAXXITEK HVT+IBD in controlled studies of chickens^{1,2}

Vaccine regimen	% protection against MD challenge	% protection against IBD challenge
PREVEXXION RN & VAXXITEK HVT+IBD	100%*	100%**

* Higher than the requested level of protection as stated by 9 CFR 113.330

** Higher than the requested level of protection as stated by 9 CFR 113.331

BENEFITS OF ADDED PROTECTION




- One hatchery administration
- Reduces the risk of vaccine confusion
- Onset of immunity from four days of age³
- Long-lasting immunity⁴ like classic serotype 1 vaccines even for long-lived birds
- Protection against the most virulent MD virus
- Delivers the right safety⁵ and efficacy⁶ balance
- Efficacious for chickens vaccinated *in ovo*⁷
- Broad spectrum protection against most pathotypes of the IBD virus

The estimated economic burden of MD may reach **US \$1 to \$2 billion annually⁸**



VALUE

A convenient 3-in-1 solution available with PREVEXXION® RN and VAXXITEK® HVT+IBD in the same ampule



Continuous evolution of virulence and emergence of hypervirulent pathotypes of GaHV-2 strains, remains the major challenge for sustainable control of this disease⁹ as confirmed by recent publications coming from diverse areas like South America or Middle East, for instance^{10,11,12}.

This is happening through a succession of steps and thus it is expected that the virulence will continue to increase in the coming years.

Two generations of Marek's disease vaccines have shown reduced efficacy over the last half century due to evolution of the virus¹³. Additionally, atrophy of lymphoid organs is a major drawback in the production of highly protective vaccines against MD¹⁴.

To decrease the chances of field MD to overcome current MD vaccines protection, while ensuring a favorable safety profile, an innovative MD vaccine has been developed by Boehringer Ingelheim as a key alternative to CVI988-based current products.

PREVEXXION RN & VAXXITEK HVT+IBD

provide **100% protection against MD challenge** and **100% protection against IBD challenge in controlled studies**^{1,2}

REFERENCES

- 1.–7. Data on file at Boehringer Ingelheim.
8. Atkins K.E. et al, Vaccination and reduced cohort duration can drive virulence evolution: Marek's disease virus and industrialized agriculture. *Evolution: International Journal of Organic Evolution*, 67(3):851-860, 2013
9. Nair, V., Spotlight on avian pathology: Marek's disease. *Avian Pathology*, Vol. 47 No.5, 440-442, 2018
10. Isabel M. Gimeno, Richard L. Witter, Aneg L. Cortes & Willie M. Reed (2011), Replication ability of three highly protective Marek's disease vaccines: implications in lymphoid, organ atrophy and protection, *Avian Pathology*, 40:6, 573-579.
11. Torres, A.C.D. et al., An Overview on Marek's Disease Virus Evolution and Evidence for Increased Virulence in Brazil, *Brazilian Journal of Poultry Science*, v.21, n.1, 001-010, 2019
12. Abdallah F. et al., Marek's Disease Virus in Egypt: historical overview and current research based on the major MDV-encoded oncogene Meq, *Hosts and Viruses*, 5(3): 35-43, 2018
13. Gimeno, I. et al. *Avian Pathology*, 40(6), 573-579, 2011
14. Schat, K. A. et al., Neoplastic diseases: Marek's disease, In *Diseases of Poultry*, 13th ed., pp. 513–552. Ames, Iowa, USA: Wiley-Blackwell Hoboken, 2013

PREVEXXION® and VAXXITEK® are registered trademarks of Boehringer Ingelheim Animal Health USA Inc.
©2021 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA.
All rights reserved. US-POU-0008-2021

Visit us at poultryhealthusa.com

